Inhaled liposomal tobramycin - Axentis Pharma AG

Drug Profile

Inhaled liposomal tobramycin - Axentis Pharma AG

Alternative Names: ARB-CF0223; Fluidosome tobramycin; Fluidosomes-tobramycin

Latest Information Update: 07 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator aRigen
  • Developer Axentis Pharma
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 07 Aug 2015 Phase-II development is ongoing in Europe
  • 16 Jul 2009 Tobramycin liposomal receives orphan drug status for Cystic fibrosis-associated respiratory tract infections caused by Burkholderia cepacia in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top